Bingham Osborn & Scarborough’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-7,062
| Closed | -$418K | – | 22 |
|
|
2021
Q3 | $418K | Buy |
7,062
+285
| +4% | +$18.8K | 0.03% | 103 |
|
|
2021
Q2 | $453K | Buy |
6,777
+16
| +0.2% | +$1.04K | 0.03% | 102 |
|
|
2021
Q1 | $427K | Buy |
6,761
+387
| +6% | +$24.1K | 0.03% | 92 |
|
|
2020
Q4 | $395K | Sell |
6,374
-68
| -1% | -$4.18K | 0.03% | 88 |
|
|
2020
Q3 | $388K | Buy |
6,442
+109
| +2% | +$6.56K | 0.03% | 107 |
|
|
2020
Q2 | $372K | Sell |
6,333
-142
| -2% | -$8.49K | 0.03% | 106 |
|
|
2020
Q1 | $361K | Buy |
6,475
+446
| +7% | +$27.3K | 0.04% | 100 |
|
|
2019
Q4 | $387K | Buy |
6,029
+470
| +8% | +$26.9K | 0.03% | 108 |
|
|
2019
Q3 | $282K | Sell |
5,559
-261
| -4% | -$12.3K | 0.03% | 116 |
|
|
2019
Q2 | $264K | Buy |
5,820
+1,376
| +31% | +$64.1K | 0.02% | 123 |
|
|
2019
Q1 | $212K | Buy |
4,444
+31
| +0.7% | +$1.54K | 0.02% | 135 |
|
|
2018
Q4 | $229K | Sell |
4,413
-1,711
| -28% | -$91.9K | 0.02% | 124 |
|
|
2018
Q3 | $380K | Buy |
6,124
+755
| +14% | +$44.8K | 0.03% | 98 |
|
|
2018
Q2 | $297K | Sell |
5,369
-18
| -0.3% | -$972 | 0.03% | 111 |
|
|
2018
Q1 | $341K | Buy |
5,387
+75
| +1% | +$4.83K | 0.03% | 100 |
|
|
2017
Q4 | $326K | Sell |
5,312
-3,064
| -37% | -$192K | 0.03% | 100 |
|
|
2017
Q3 | $534K | Buy |
8,376
+146
| +2% | +$8.53K | 0.05% | 66 |
|
|
2017
Q2 | $459K | Sell |
8,230
-1,141
| -12% | -$62.1K | 0.04% | 70 |
|
|
2017
Q1 | $510K | Buy |
9,371
+1,461
| +18% | +$80.1K | 0.05% | 65 |
|
|
2016
Q4 | $462K | Buy |
7,910
+141
| +2% | +$7.71K | 0.05% | 69 |
|
|
2016
Q3 | $419K | Sell |
7,769
-539
| -6% | -$34.6K | 0.04% | 77 |
|
|
2016
Q2 | $611K | Buy |
8,308
+89
| +1% | +$6.29K | 0.07% | 60 |
|
|
2016
Q1 | $525K | Buy |
8,219
+650
| +9% | +$41K | 0.06% | 67 |
|
|
2015
Q4 | $521K | Sell |
7,569
-1,550
| -17% | -$102K | 0.06% | 67 |
|
|
2015
Q3 | $540K | Buy |
9,119
+289
| +3% | +$18.3K | 0.07% | 62 |
|
|
2015
Q2 | $588K | Buy |
8,830
+75
| +0.9% | +$4.94K | 0.07% | 59 |
|
|
2015
Q1 | $565K | Sell |
8,755
-680
| -7% | -$42.6K | 0.07% | 61 |
|
|
2014
Q4 | $557K | Buy |
9,435
+145
| +2% | +$8.18K | 0.07% | 66 |
|
|
2014
Q3 | $475K | Sell |
9,290
-376
| -4% | -$18.8K | 0.06% | 71 |
|
|
2014
Q2 | $469K | Sell |
9,666
-475
| -5% | -$23.4K | 0.06% | 66 |
|
|
2014
Q1 | $527K | Hold |
10,141
| – | – | 0.07% | 60 |
|
|
2013
Q4 | $539K | Buy |
10,141
+1,600
| +19% | +$81.5K | 0.08% | 54 |
|
|
2013
Q3 | $395K | Buy |
8,541
+2,061
| +32% | +$90.5K | 0.06% | 61 |
|
|
2013
Q2 | $290K | Buy |
+6,480
| New | +$281K | 0.05% | 62 |
|
Other funds holding BMY
Bingham Osborn & Scarborough's BMY Position: Q4 2021 in Review
Bingham Osborn & Scarborough sold out of Bristol-Myers Squibb (BMY) in Q4 2021, closing a stake of 7,062 shares — an estimated $418K sold.
Bingham Osborn & Scarborough first reported a position in BMY in Q2 2013 and held it in 34 quarters. The position peaked at $611K in Q2 2016. 2,444 funds tracked by Wall St. Rank hold BMY as of Q4 2021.
- Bingham Osborn & Scarborough reported no remaining Bristol-Myers Squibb position as of Q4 2021 after selling out during the quarter.
- Bingham Osborn & Scarborough sold 7,062 Bristol-Myers Squibb shares in Q4 2021, an estimated $418K.
- Bingham Osborn & Scarborough first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 34 quarters.
- Bingham Osborn & Scarborough's Bristol-Myers Squibb position peaked at $611K in Q2 2016.
- 2,444 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2021.
Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.